within Pharmacolibrary.Drugs.ATC.A;

model A08AA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.288 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.0324,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Setmelanotide is a melanocortin 4 receptor (MC4R) agonist indicated for the treatment of obesity due to certain rare genetic deficiencies, such as POMC, PCSK1, or LEPR deficiency. It is approved for clinical use by the FDA in these indications and is administered as a chronic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are mainly derived from adult and pediatric patients (age 6-65 years) with obesity due to genetic deficiencies; subcutaneous administration.</p><h4>References</h4><ol><li><p>Wang, S, et al., &amp; Schwendeman, SP (2023). Aqueous remote loading of setmelanotide in poly(lactic-co-glycolic acid) microspheres for long-term obesity treatment. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 364 589–600. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2023.09.015&quot;>10.1016/j.jconrel.2023.09.015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37678438/&quot;>https://pubmed.ncbi.nlm.nih.gov/37678438</a></p></li><li><p> (2021). Setmelanotide (Imcivree) for rare genetic forms of obesity. <i>The Medical letter on drugs and therapeutics</i> 63(1629) e3–e4. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34544109/&quot;>https://pubmed.ncbi.nlm.nih.gov/34544109</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A08AA12;
